KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Construction in Progress (2016 - 2024)

Nektar Therapeutics has reported Construction in Progress over the past 15 years, most recently at $245000.0 for Q4 2024.

  • Quarterly results put Construction in Progress at $245000.0 for Q4 2024, down 66.85% from a year ago — trailing twelve months through Dec 2024 was $245000.0 (down 66.85% YoY), and the annual figure for FY2024 was $245000.0, down 66.85%.
  • Construction in Progress for Q4 2024 was $245000.0 at Nektar Therapeutics, up from $138000.0 in the prior quarter.
  • Over the last five years, Construction in Progress for NKTR hit a ceiling of $7.2 million in Q4 2021 and a floor of $138000.0 in Q3 2024.
  • Median Construction in Progress over the past 5 years was $731500.0 (2023), compared with a mean of $1.8 million.
  • Peak annual rise in Construction in Progress hit 57.05% in 2024, while the deepest fall reached 71.72% in 2024.
  • Nektar Therapeutics' Construction in Progress stood at $4.7 million in 2020, then skyrocketed by 52.4% to $7.2 million in 2021, then crashed by 64.68% to $2.5 million in 2022, then tumbled by 70.79% to $739000.0 in 2023, then tumbled by 66.85% to $245000.0 in 2024.
  • The last three reported values for Construction in Progress were $245000.0 (Q4 2024), $138000.0 (Q3 2024), and $724000.0 (Q2 2024) per Business Quant data.